Symbols / ACAD
ACAD Chart
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.11B |
| Enterprise Value | 3.39B | Income | 391.00M | Sales | 1.07B |
| Book/sh | 7.25 | Cash/sh | 4.84 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 15.66 | Forward P/E | 26.51 | PEG | — |
| P/S | 3.83 | P/B | 3.35 | P/C | — |
| EV/EBITDA | 29.10 | EV/Sales | 3.17 | Quick Ratio | 3.49 |
| Current Ratio | 3.83 | Debt/Eq | 3.30 | LT Debt/Eq | — |
| EPS (ttm) | 1.55 | EPS next Y | 0.92 | EPS Growth | 86.30% |
| Revenue Growth | 9.40% | Earnings | 2026-05-06 | ROA | 4.76% |
| ROE | 39.89% | ROIC | — | Gross Margin | 91.69% |
| Oper. Margin | 6.12% | Profit Margin | 36.49% | Shs Outstand | 169.18M |
| Shs Float | 125.46M | Short Float | 8.24% | Short Ratio | 6.76 |
| Short Interest | — | 52W High | 28.35 | 52W Low | 13.40 |
| Beta | — | Avg Volume | 1.45M | Volume | 1.03M |
| Target Price | $31.55 | Recom | Buy | Prev Close | $24.64 |
| Price | $24.27 | Change | -1.48% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$31.55
Mean price target
2. Current target
$24.28
Latest analyst target
3. DCF / Fair value
$23.25
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$24.28
Low
$17.00
High
$40.00
Mean
$31.55
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | TD Cowen | Buy → Buy | $37 |
| 2026-02-26 | main | RBC Capital | Outperform → Outperform | $30 |
| 2026-02-26 | main | Citizens | Market Outperform → Market Outperform | $35 |
| 2026-02-26 | main | Stifel | Hold → Hold | $24 |
| 2026-02-24 | init | Wolfe Research | — → Outperform | $33 |
| 2026-02-23 | up | Mizuho | Neutral → Outperform | $35 |
| 2026-02-06 | main | Oppenheimer | Perform → Perform | $23 |
| 2026-02-03 | main | RBC Capital | Outperform → Outperform | $31 |
| 2026-02-03 | reit | Citizens | Market Outperform → Market Outperform | $34 |
| 2026-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $37 |
| 2026-01-06 | main | Citigroup | Buy → Buy | $36 |
| 2026-01-06 | main | UBS | Buy → Buy | $40 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $37 |
| 2025-12-11 | main | Stifel | Hold → Hold | $25 |
| 2025-12-02 | main | Mizuho | Neutral → Neutral | $29 |
| 2025-11-17 | main | JP Morgan | Overweight → Overweight | $31 |
| 2025-11-06 | main | RBC Capital | Outperform → Outperform | $32 |
| 2025-11-06 | main | Needham | Buy → Buy | $29 |
| 2025-10-21 | init | Citigroup | — → Buy | $33 |
| 2025-09-29 | main | JP Morgan | Overweight → Overweight | $33 |
- Acadia Pharmaceuticals (ACAD) Margin Expansion To 36.5% Tests Bearish Earnings Narratives - simplywall.st Fri, 27 Feb 2026 10
- Will ACADIA Pharmaceuticals' (ACAD) 2025 Earnings Beat and 2026 Guidance Shift Its Growth Narrative? - Yahoo Finance hu, 26 Feb 2026 23
- Watch Acadia’s March investor fireside chats online for a month - Stock Titan Mon, 23 Feb 2026 21
- What is HC Wainwright's Estimate for ACAD Q3 Earnings? - MarketBeat Fri, 27 Feb 2026 12
- ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth - The Globe and Mail Fri, 27 Feb 2026 04
- TD Cowen Raises Price Target for ACADIA Pharmaceuticals (ACAD) | - GuruFocus hu, 26 Feb 2026 18
- New Analyst Forecast: $ACAD Given $35 Price Target - Quiver Quantitative Mon, 23 Feb 2026 12
- Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates - Yahoo Finance hu, 26 Feb 2026 00
- TD Cowen Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat hu, 26 Feb 2026 18
- ACAD: Citizens Analyst Raises Price Target to $35.00, Maintains Market Outperform Rating | ACAD Stock News - GuruFocus hu, 26 Feb 2026 15
- ACAD: Stifel Lowers Price Target, Maintains Hold Rating | ACAD S - GuruFocus hu, 26 Feb 2026 15
- A Look At ACADIA Pharmaceuticals (ACAD) Valuation After A 29.11% One Year Total Return - simplywall.st hu, 26 Feb 2026 09
- Citigroup Inc. Sells 92,770 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat Wed, 25 Feb 2026 09
- ACAD: RBC Capital Lowers Price Target While Maintaining Outperfo - GuruFocus hu, 26 Feb 2026 16
- Wolfe Research Upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) to "Strong-Buy" - MarketBeat Wed, 25 Feb 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6950 | 162491.0 | — | Sale at price 23.38 per share. | RHODES JENNIFER J. | Officer | — | 2026-02-09 00:00:00 | D |
| 1 | 12944 | nan | — | — | RHODES JENNIFER J. | Officer | — | 2026-02-06 00:00:00 | D |
| 2 | 4084 | 96754.0 | — | Sale at price 23.69 per share. | KIHARA JAMES | Officer | — | 2025-11-18 00:00:00 | D |
| 3 | 10262 | 243114.0 | — | Sale at price 23.69 per share. | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-11-18 00:00:00 | D |
| 4 | 19826 | nan | — | — | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-11-17 00:00:00 | D |
| 5 | 7932 | nan | — | — | KIHARA JAMES | Officer | — | 2025-11-17 00:00:00 | D |
| 6 | 30000 | 670983.0 | — | Sale at price 22.37 per share. | DALY JAMES M. | Director | — | 2025-11-10 00:00:00 | D |
| 7 | 3498 | 82728.0 | — | Sale at price 23.65 per share. | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-09-15 00:00:00 | D |
| 8 | 6815 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-09-12 00:00:00 | D |
| 9 | 1600 | 41560.0 | — | Sale at price 25.98 per share. | GAROFALO ELIZABETH AMY M.D. | Director | — | 2025-09-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 17.95M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.12 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -46.35M | -67.83M | -221.57M | -167.09M |
| TotalUnusualItems | 146.51M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 146.51M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | 226.45M | -61.29M | -215.97M | -167.87M |
| ReconciledDepreciation | 15.88M | 5.55M | 2.03M | 3.34M |
| ReconciledCostOfRevenue | 81.84M | 41.64M | 10.17M | 19.14M |
| EBITDA | 100.16M | -67.83M | -221.57M | -167.09M |
| EBIT | 84.28M | -73.38M | -223.60M | -170.44M |
| NetInterestIncome | 25.46M | 17.23M | 6.61M | 591.00K |
| InterestIncome | 25.46M | 17.23M | 6.61M | 591.00K |
| NormalizedIncome | 97.89M | -61.29M | -215.97M | -167.87M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 226.45M | -61.29M | -215.97M | -167.87M |
| TotalExpenses | 873.52M | 799.82M | 740.83M | 654.58M |
| TotalOperatingIncomeAsReported | 230.79M | -73.38M | -223.60M | -170.44M |
| DilutedAverageShares | 166.36M | 163.82M | 161.68M | 160.49M |
| BasicAverageShares | 165.72M | 163.82M | 161.68M | 160.49M |
| DilutedEPS | 1.36 | -0.37 | -1.34 | -1.05 |
| BasicEPS | 1.37 | -0.37 | -1.34 | -1.05 |
| DilutedNIAvailtoComStockholders | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncomeCommonStockholders | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncome | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncomeIncludingNoncontrollingInterests | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncomeContinuousOperations | 226.45M | -61.29M | -215.97M | -167.87M |
| TaxProvision | 31.62M | 10.25M | 2.53M | 351.00K |
| PretaxIncome | 258.07M | -51.04M | -213.44M | -167.52M |
| OtherIncomeExpense | 148.34M | 5.11M | 3.54M | 2.33M |
| OtherNonOperatingIncomeExpenses | 1.82M | 5.11M | 3.54M | 2.33M |
| SpecialIncomeCharges | 146.51M | 0.00 | 0.00 | |
| GainOnSaleOfPPE | 146.51M | 0.00 | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 25.46M | 17.23M | 6.61M | 591.00K |
| InterestIncomeNonOperating | 25.46M | 17.23M | 6.61M | 591.00K |
| OperatingIncome | 84.28M | -73.38M | -223.60M | -170.44M |
| OperatingExpense | 791.68M | 758.18M | 730.66M | 635.44M |
| ResearchAndDevelopment | 303.25M | 351.62M | 361.57M | 239.41M |
| SellingGeneralAndAdministration | 488.43M | 406.56M | 369.09M | 396.03M |
| GeneralAndAdministrativeExpense | 396.03M | |||
| OtherGandA | 396.03M | |||
| GrossProfit | 875.96M | 684.80M | 507.07M | 465.00M |
| CostOfRevenue | 81.84M | 41.64M | 10.17M | 19.14M |
| TotalRevenue | 957.80M | 726.44M | 517.24M | 484.14M |
| OperatingRevenue | 957.80M | 726.44M | 517.24M | 484.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 166.71M | 164.65M | 162.06M | 161.01M |
| ShareIssued | 166.71M | 164.65M | 162.06M | 161.01M |
| TotalDebt | 51.99M | 57.20M | 62.00M | 64.43M |
| TangibleBookValue | 613.01M | 366.26M | 400.41M | 540.89M |
| InvestedCapital | 732.79M | 431.75M | 400.41M | 540.89M |
| WorkingCapital | 543.45M | 361.87M | 382.31M | 521.75M |
| NetTangibleAssets | 613.01M | 366.26M | 400.41M | 540.89M |
| CapitalLeaseObligations | 51.99M | 57.20M | 62.00M | 64.43M |
| CommonStockEquity | 732.79M | 431.75M | 400.41M | 540.89M |
| TotalCapitalization | 732.79M | 431.75M | 400.41M | 540.89M |
| TotalEquityGrossMinorityInterest | 732.79M | 431.75M | 400.41M | 540.89M |
| StockholdersEquity | 732.79M | 431.75M | 400.41M | 540.89M |
| GainsLossesNotAffectingRetainedEarnings | 292.00K | 24.00K | -975.00K | -192.00K |
| OtherEquityAdjustments | 292.00K | 24.00K | -975.00K | -192.00K |
| RetainedEarnings | -2.20B | -2.43B | -2.37B | -2.15B |
| AdditionalPaidInCapital | 2.94B | 2.86B | 2.77B | 2.69B |
| CapitalStock | 16.00K | 16.00K | 16.00K | 16.00K |
| CommonStock | 16.00K | 16.00K | 16.00K | 16.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 454.96M | 317.20M | 187.40M | 159.23M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 60.09M | 62.95M | 61.77M | 63.16M |
| OtherNonCurrentLiabilities | 18.06M | 15.15M | 9.07M | 7.03M |
| LongTermDebtAndCapitalLeaseObligation | 42.04M | 47.80M | 52.70M | 56.13M |
| LongTermCapitalLeaseObligation | 42.04M | 47.80M | 52.70M | 56.13M |
| CurrentLiabilities | 394.87M | 254.25M | 125.63M | 96.07M |
| CurrentDebtAndCapitalLeaseObligation | 9.96M | 9.40M | 9.30M | 8.30M |
| CurrentCapitalLeaseObligation | 9.96M | 9.40M | 9.30M | 8.30M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 36.55M | 42.72M | 28.02M | 25.90M |
| PayablesAndAccruedExpenses | 348.36M | 202.13M | 88.30M | 61.87M |
| CurrentAccruedExpenses | 320.15M | 183.02M | 75.18M | 54.99M |
| Payables | 28.21M | 19.11M | 13.12M | 6.88M |
| TotalTaxPayable | 12.02M | 1.56M | 377.00K | |
| AccountsPayable | 16.19M | 17.54M | 12.75M | 6.88M |
| TotalAssets | 1.19B | 748.96M | 587.81M | 700.12M |
| TotalNonCurrentAssets | 249.44M | 132.83M | 79.88M | 82.30M |
| OtherNonCurrentAssets | 78.87M | 10.87M | 18.28M | 15.98M |
| GoodwillAndOtherIntangibleAssets | 119.78M | 65.49M | 0.00 | 0.00 |
| NetPPE | 50.79M | 56.47M | 61.59M | 66.31M |
| AccumulatedDepreciation | -10.22M | -9.56M | -8.10M | -6.18M |
| GrossPPE | 61.00M | 66.02M | 69.69M | 72.50M |
| Leases | 3.75M | 3.75M | 3.70M | 3.70M |
| ConstructionInProgress | 523.00K | 0.00 | ||
| OtherProperties | 46.57M | 51.85M | 55.57M | 58.27M |
| MachineryFurnitureEquipment | 10.16M | 10.42M | 10.42M | 10.54M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 938.32M | 616.12M | 507.94M | 617.82M |
| PrepaidAssets | 55.68M | 39.09M | 21.40M | 23.89M |
| Inventory | 21.95M | 35.82M | 6.64M | 7.88M |
| FinishedGoods | 1.93M | 1.11M | ||
| WorkInProcess | 4.43M | 6.77M | ||
| RawMaterials | 283.00K | 0.00 | ||
| Receivables | 104.69M | 102.35M | 63.08M | 65.34M |
| AccruedInterestReceivable | 5.96M | 4.08M | 885.00K | 978.00K |
| AccountsReceivable | 98.74M | 98.27M | 62.20M | 64.37M |
| CashCashEquivalentsAndShortTermInvestments | 755.99M | 438.87M | 416.82M | 520.71M |
| OtherShortTermInvestments | 436.40M | 250.21M | 301.98M | 373.27M |
| CashAndCashEquivalents | 319.59M | 188.66M | 114.85M | 147.44M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 157.20M | -23.35M | -114.03M | -126.78M |
| IssuanceOfCapitalStock | 6.84M | 25.13M | 8.20M | 18.16M |
| CapitalExpenditure | -523.00K | -40.05M | -1.12M | |
| IncomeTaxPaidSupplementalData | 19.52M | 5.85M | 2.19M | 1.04M |
| EndCashPosition | 328.36M | 194.43M | 120.62M | 153.21M |
| BeginningCashPosition | 194.43M | 120.62M | 153.21M | 331.80M |
| EffectOfExchangeRateChanges | -94.00K | -18.00K | 6.00K | 7.00K |
| ChangesInCash | 134.03M | 73.83M | -32.59M | -178.60M |
| FinancingCashFlow | 6.84M | 25.13M | 8.20M | 18.16M |
| CashFlowFromContinuingFinancingActivities | 6.84M | 25.13M | 8.20M | 18.16M |
| NetCommonStockIssuance | 6.84M | 25.13M | 8.20M | 18.16M |
| CommonStockIssuance | 6.84M | 25.13M | 8.20M | 18.16M |
| InvestingCashFlow | -30.54M | 32.00M | 73.24M | -71.10M |
| CashFlowFromContinuingInvestingActivities | -30.54M | 32.00M | 73.24M | -71.10M |
| NetOtherInvestingChanges | 146.51M | |||
| NetInvestmentPurchaseAndSale | -176.53M | 72.05M | 73.24M | -69.98M |
| SaleOfInvestment | 328.56M | 442.03M | 436.42M | 422.82M |
| PurchaseOfInvestment | -505.10M | -369.99M | -363.17M | -492.80M |
| NetIntangiblesPurchaseAndSale | 0.00 | -40.00M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -523.00K | -50.00K | 0.00 | -1.12M |
| PurchaseOfPPE | -523.00K | -50.00K | 0.00 | -1.12M |
| OperatingCashFlow | 157.72M | 16.70M | -114.03M | -125.66M |
| CashFlowFromContinuingOperatingActivities | 157.72M | 16.70M | -114.03M | -125.66M |
| ChangeInWorkingCapital | 4.16M | 18.13M | 37.99M | -24.82M |
| ChangeInOtherCurrentLiabilities | -4.69M | 201.00K | -5.88M | -3.58M |
| ChangeInOtherCurrentAssets | 7.62M | 5.74M | 6.52M | 6.30M |
| ChangeInPayablesAndAccruedExpense | 69.71M | 97.97M | 30.18M | -10.07M |
| ChangeInAccruedExpense | 71.06M | 93.17M | 24.31M | -8.46M |
| ChangeInPayable | -1.35M | 4.80M | 5.87M | -1.62M |
| ChangeInAccountPayable | -1.35M | 4.80M | 5.87M | -1.62M |
| ChangeInPrepaidAssets | -16.59M | -17.69M | 2.49M | 1.80M |
| ChangeInInventory | -49.55M | -28.81M | 2.42M | -4.21M |
| ChangeInReceivables | -2.35M | -39.27M | 2.26M | -15.06M |
| ChangesInAccountReceivables | -472.00K | -36.07M | 2.17M | -16.12M |
| StockBasedCompensation | 67.05M | 66.42M | 68.20M | 63.62M |
| AmortizationOfSecurities | -9.30M | -7.53M | -2.74M | 2.40M |
| DepreciationAmortizationDepletion | 15.88M | 5.55M | 2.03M | 3.34M |
| DepreciationAndAmortization | 15.88M | 5.55M | 2.03M | 3.34M |
| AmortizationCashFlow | 14.96M | 4.09M | 0.00 | 1.11M |
| AmortizationOfIntangibles | 14.96M | 4.09M | 0.00 | 1.11M |
| Depreciation | 920.00K | 1.46M | 2.03M | 2.24M |
| OperatingGainsLosses | -146.51M | -4.58M | -3.54M | -2.33M |
| GainLossOnInvestmentSecurities | -4.58M | -3.54M | -2.33M | |
| NetIncomeFromContinuingOperations | 226.45M | -61.29M | -215.97M | -167.87M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACAD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|